| Literature DB >> 31615330 |
Bailey G Hannon1, Stephen A Schwaner1, Elizabeth M Boazak2, Brandon G Gerberich2, Erin J Winger3, Mark R Prausnitz3,2, C Ross Ethier1,2.
Abstract
Scleral stiffening has been proposed as a therapy for glaucoma and myopia. Previous in vivo studies have evaluated the efficacy of scleral stiffening after multiple treatments with a natural collagen crosslinker, genipin. However, multiple injections limit clinical translatability. Here, we examined whether scleral stiffening was maintained after four weeks following a single genipin treatment. Eyes from brown Norway rats were treated in vivo with a single 15 mM genipin retrobulbar injection, sham retrobulbar injection, or were left naive. Eyes were enucleated either 1 day or four weeks post-injection and underwent whole globe inflation testing. We assessed first principal Lagrange strain of the posterior sclera using digital image correlation as a proxy for scleral stiffness. Four weeks post-injection, genipin treatment resulted in a 58% reduction in scleral strain as compared to controls (p = 0.005). We conclude that a single in vivo injection of genipin effectively stiffened rat sclera for at least four weeks which motivates further functional studies and possible clinical translation of genipin-induced scleral stiffening.Entities:
Keywords: collagen-crosslinking; genipin; glaucoma; myopia; sclera; stiffening
Year: 2019 PMID: 31615330 PMCID: PMC6833323 DOI: 10.1098/rsif.2019.0427
Source DB: PubMed Journal: J R Soc Interface ISSN: 1742-5662 Impact factor: 4.118